Oculis (NASDAQ:OCS) Stock Price Down 5.6% - Time to Sell?

Key Points

• Oculis shares fell 5.6% to about $8.82 on sharply reduced trading volume, remaining below both its 50-day and 200-day moving averages.
• Analyst sentiment is broadly positive, with nine Buy ratings and one Sell rating producing a “Moderate Buy” consensus and an average price target of $39.44, despite differing individual targets.
• The clinical-stage biopharmaceutical company remains unprofitable, reporting a quarterly loss of $0.20 per share and minimal revenue, though it maintains strong liquidity with a quick ratio of 8.35 and negligible debt.

Oculis Holding AG (NASDAQ:OCS - Get Free Report) was down 5.6% during trading on Thursday. The company traded as low as $9.03 and last traded at $8.8170. Approximately 27,327 shares changed hands during trading, a decline of 94% from the average daily volume of 428,233 shares. The stock had previously closed at $9.34.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on OCS. JPMorgan Chase & Co. dropped their price objective on shares of Oculis from $23.00 to $20.00 and set an "overweight" rating on the stock in a research note on Friday, August 14th. HC Wainwright increased their target price on Oculis from $26.00 to $39.00 and gave the company a "buy" rating in a research report on Friday, September 18th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Oculis in a report on Friday, July 17th. Finally, Wall Street Zen upgraded Oculis from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 8th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $39.44.

Oculis Trading Down 5.3%

The company's 50 day simple moving average is $11.59 and its two-hundred day simple moving average is $17.87. The company has a quick ratio of 8.35, a current ratio of 8.35 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $513.10 million, a price-to-earnings ratio of -5.09 and a beta of 0.52.

Oculis (NASDAQ:OCS - Get Free Report) last posted its quarterly earnings data on Tuesday, June 30th. The company reported ($0.20) earnings per share for the quarter. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%.The business had revenue of $0.38 million during the quarter. As a group, research analysts anticipate that Oculis Holding AG will post -2.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Bank of America Corp DE grew its position in Oculis by 9.1% during the 1st quarter. Bank of America Corp DE now owns 69,764 shares of the company's stock worth $1,855,000 after purchasing an additional 5,813 shares during the period. Koshinski Asset Management Inc. acquired a new position in Oculis during the first quarter worth $238,000. Himension Capital Singapore PTE. LTD. purchased a new position in Oculis during the first quarter valued at $503,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Oculis in the first quarter valued at about $776,000. Finally, Squarepoint Ops LLC increased its stake in shares of Oculis by 326.4% during the second quarter. Squarepoint Ops LLC now owns 61,605 shares of the company's stock worth $854,000 after purchasing an additional 47,158 shares in the last quarter. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

Oculis Company Profile

Oculis is a clinical-stage biopharmaceutical company focused on developing ophthalmic therapies for eye diseases and vision loss. The company uses proprietary drug-delivery technologies designed to improve the delivery of treatments to specific tissues in the eye, with the goal of offering effective and convenient alternatives to injections or other invasive procedures.

Oculis' pipeline includes OCS-01, a topical eye-drop formulation of dexamethasone being developed for diabetic macular edema and inflammation following ocular surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.